Literature DB >> 8028379

St. Jude Medical prosthesis in children.

M Ibrahim1, J Cleland, H O'Kane, D Gladstone, C Mullholland, B Craig.   

Abstract

From December 1980 through April 1992, 20 children 2 to 18 years of age underwent valve replacement with the St. Jude Medical prosthesis. Nine children underwent aortic valve replacement, eight underwent mitral valve replacement, and the three children with corrected transposition underwent left-sided tricuspid valve replacement. Of the 20 patients, 17 underwent 23 previous procedures. All but five patients received adequate adult-sized prostheses. There was one hospital death (5%). All hospital survivors received maintenance doses of sodium warfarin. Follow-up was 100% complete with a total of 106 patient-years. There were no late deaths and no thromboembolic or anticoagulant-related bleeding. None of the patients had prosthetic valve endocarditis or a periprosthetic leak. Reoperation was not required in any patient. The great majority of the children (16 of 19) were in New York Heart Association functional class I, two were in class II, and one with complex congenital heart disease was in class III at the time this article was written. This study illustrates the excellent results of cardiac valve replacement with the St. Jude Medical prosthesis in children and confirms the safety of sodium warfarin in this age group.

Entities:  

Mesh:

Year:  1994        PMID: 8028379

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  2 in total

1.  Mitral valve replacement using mechanical prostheses in children: early and long-term outcomes.

Authors:  Hyung-Tae Sim; Seung-Cheol Lee; Hong Ju Shin; Jeong-Jun Park; Tae-Jin Yun; Won-Kyoung Jhang; Dong Man Seo
Journal:  Pediatr Cardiol       Date:  2012-02-16       Impact factor: 1.655

2.  Mitral valve replacement in children: mortality, morbidity, and haemodynamic status up to medium term follow up.

Authors:  C van Doorn; R Yates; V Tsang; M deLeval; M Elliott
Journal:  Heart       Date:  2000-12       Impact factor: 5.994

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.